Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is
35.577 BRL
71.79 B BRL
302.49 B BRL
1.69 B
About NOVARTIS N
Sector
Industry
CEO
Vasant Narasimhan
Website
Headquarters
Basel
Founded
1996
ISIN
BRN1VSBDR006
FIGI
BBG00XX9KCR3
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
NVS 1H Swing Long Conservative Trend TradeConservative Trend Trade
+ long impulse
+ 1/2 correction
+ T2 level
+ support level
- biggest volume 2Sp-
Calculated affordable stop limit
1 to 2 R/R within 1H range take profit
Daily Trend
"+ long impulse
+ 1/2 correction
+ JOC level
+ support level
- above 1/2 of entire 1D wave at the support le
Investing in Health: Reasons Why Novartis AG Stock Stands OutIn an era where health is wealth, and the global healthcare sector is booming like never before, savvy investors are looking for opportunities that promise growth and a meaningful impact on people’s lives. Enter Novartis AG—a powerhouse in pharmaceuticals that’s not only redefining treatments but al
NVS Novartis AG Options Ahead of EarningsAnalyzing the options chain and the chart patterns of NVS Novartis AG prior to the earnings report this week,
I would consider purchasing the 110usd strike price Calls with
an expiration date of 2024-8-16,
for a premium of approximately $3.30.
If these options prove to be profitable prior to the ear
Novartis Strikes $1.01 Bln Deal with Arvinas for Prostate DrugsNovartis ( NYSE:NVS ), the Swiss pharmaceutical giant, has made a strategic move in the field of cancer treatment by securing a licensing agreement with Arvinas, a U.S. biotech company. The deal, valued at up to $1.01 billion, grants Novartis access to Arvinas' experimental prostate cancer drug, ARV
Investment Opportunity Novartis AG (short)Wyckoff in Daily/Weekly timeframe, we can observe the price took the upside liquidity (bc) before breaking the structure downside.
I'm expecting the price to go back on my grey zone (supply) around 99 before continuing the bearish trend.
First target 88 (sc)
Second target 83 (demand zone)
I will l
Longing Novartis (NVS) Longing Novartis (NVS): A Strategic Investment Amidst Geopolitical Tensions
This article presents a compelling rationale for considering a long position in Novartis (NVS) stock. The primary driving factor behind this investment strategy is Novartis' close association with Sandoz (SDZ) following the
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US66989HAS7
NOVARTIS CAP 20/50Yield to maturity
6.96%
Maturity date
Aug 14, 2050
XPND
NOVARTIS CAPITAL 15/45Yield to maturity
6.19%
Maturity date
Nov 20, 2045
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042Yield to maturity
6.16%
Maturity date
Sep 21, 2042
US66989HAH1
NOVARTIS CAPITAL 14/44Yield to maturity
6.03%
Maturity date
May 6, 2044
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054Yield to maturity
5.93%
Maturity date
Sep 18, 2054
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034Yield to maturity
5.15%
Maturity date
Sep 18, 2034
US66989HAR9
NOVARTIS CAP 20/30Yield to maturity
4.88%
Maturity date
Aug 14, 2030
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031Yield to maturity
4.71%
Maturity date
Sep 18, 2031
XPNC
NOVARTIS CAPITAL 15/25Yield to maturity
4.57%
Maturity date
Nov 20, 2025
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029Yield to maturity
4.49%
Maturity date
Sep 18, 2029
US66989HAN8
NOVARTIS CAPITAL 17/27Yield to maturity
4.38%
Maturity date
May 17, 2027
See all N1VS34 bonds
Curated watchlists where N1VS34 is featured.